Type 1 hypersensitivity, i.e. IgE-mediated allergy, is a substantial health problem in countries having adapted to Western lifestyle (1;2). Grass pollen and house dust mite are the most important allergen sources world-wide (3), but on a regional basis local pollen may be the cause of even higher prevalences of sensitization. In Scandinavia, inhalation allergy to birch pollen is among the most prevalent (4) . Patients allergic to birch pollen most often also react to pollens of the related trees alder and hazel (5) prolonging the season with symptom load. Hazel pollinates in February-March, alder typically in March, and birch in April-May. Birch is the quantitatively dominating species reaching average pollen counts in the peak season of about 500 grains per m 3 , which is about 10 times the level of hazel and alder, and consequently most patients are sensitized to birch pollen. Birch pollen allergic patients have an increased risk of symptoms upon ingestion of foods, such as nuts and certain vegetables and fruits, for example apple (6;7) . Symptoms induced by the foods are typically mild and restricted to the region around the mouth, for example itching and swelling of lip or tongue and throat irritation. This phenomenon is referred to as the Oral Allergy Syndrome, (OAS) (8;9) . Analysis of allergic patients serum IgE by crossed immuno-electrophoresis have revealed that all birch pollen allergic patients have IgE directed to the major allergen Bet v 1 (4) . Although patients may occasionally react to other allergens, IgE to Bet v 1 accounts for more than 90 % of the IgE directed towards birch pollen allergens (4) . Molecular studies have shown the presence of major allergens homologous to Bet v 1 in extracts of hazel and alder pollen. The current model for cross-reactivity is that the major allergens with ≥ 75 % sequence identity have common molecular structures (i.e. epitopes) on their surfaces, that are recognized by the same patient IgE antibodies (10) . Also, more distantly related species, such as apple, contain molecules homologous to Bet v 1 (11;12) . Mal d 1, the major allergen in apple, is a 14 KDa protein that shares 55-65% amino acid sequence identity with Bet v 1. The molecular mechanism underlying OAS upon ingestion of apple is thought to be the same as those responsible for antibody cross-reactivity in general. Sequence similarity between Mal d 1 and Bet v 1 is obviously reduced compared to the more closely related species (hazel, alder), but studies comparing the molecular surfaces of Bet v 1 and Mal d 1 suggest that the OAS is indeed caused by IgE binding to epitopes which are shared between Bet v 1 and Mal d 1 (13) . Still, the conserved surface areas between Bet v 1 and Mal d 1 are smaller compared to conserved surface areas between Bet v 1 and Aln g 1, the major allergen of alder pollen, and consequently, only a fraction of birch allergic patients have IgE directed to the conserved surface areas in Mal d 1 and therefore display OAS upon ingestion of apple. The dynamics of the processes taking place at the surface of mast cells and basophils have been described in some detail. IgE molecules are anchored to the cell surface through high affinity FcεRI receptors with the ability to float freely over the cell surface. Effector cell activation occurs after simultaneous binding of the same allergen molecule by two or more IgE antibodies (14) . As shown in a recent article (15) using a panel of recombinant allergen specific IgE antibodies activation of signal transduction requires that the first interaction is of medium to high affinity to withhold the allergen near the cell surface. The receptorbound IgE molecules then float to the vicinity of the complex facilitating the second interaction. A consequence of this cooperativity is that if the first interaction is of high affinity the affinity of the second interaction is not critical and even low affinity interactions may play a significant role in crosslinking and therefore also effector cell activation. This suggests that an IgE-allergen interaction through a single high affinity antibody may manifest into clinically significant cross-reactivity in the presence of an additional IgE-allergen interaction of any affinity. Still, the degree of similarity of molecular surface structures on related but nonidentical allergens needed to support relevant cross-reactivity in relation to allergy and OAS is still uncertain. Here a well characterized conformational B-cell epitope from the major birch pollen allergen Bet v 1 was re-created onto the surface of Mal d 1, and the kinetic parameters characterizing antibody-epitope interactions were measured using Biacore technology. Furthermore, the allergenicity of several mutated Mal d 1 variants was investigated in IgE binding assays with birch patient serum IgE and in basophil histamine release experiments with blood from birch allergic patients to investigate the effects on cross-reactivity of increasing or reducing surface similarity to Bet v 1 of Mal d 1 variants.
EXPERIMENTAL PROCEDURES
Cloning of constructs Generation of rMal d 1 variants was initiated on a previously cloned DNA construct (13) coding for Mal d 1 isoform (Genbank accession no.: Q8L6K9) inserted into the Escherichia coli expression vector pMAL-c (New England Biolabs, Hertfordshire, UK). First, nucleotides targeted for mutation that were located closely together in the DNA sequence were mutated by PCR-based overlap extension using sense and anti-sense mutation-specific oligonucleotide primers accommodating each mutation along with sense and anti-sense oligonucleotide primers accommodating either upstream or downstream neighbor mutations or the Nterminus/C-terminus of Mal d 1, respectively. Secondly, the PCR products were purified, mixed and used as templates in a PCR assembling reaction with oligonucleotide primers accommodating the N-terminus and C-terminus of rMal d October, 1998) , in brief the monoclonal antibody BV16 (1 to 10 µg/ml in HBS-EP biacore buffer) was injected into the four flow-channels on the Biacore Sensor Chip CM5 for 300 sec at a flow rate of 30 µL/min (charging phase), followed by a 150 sec flow (30 µL/min) of HBS-EP buffer (equilibrium phase). The antigen i.e. rBet v 1 (Z80104), rMal d 1 (Q8L6K9) or one of the rMal d 1 variants was injected for 180 sec (association phase), followed by a HBS-EP buffer flow (30 µL/min) for up to 1000 sec (dissociation phase), and the flow-channels were regenerated by a pulse of 10 mM glycine solution, pH 1. 
Specific human serum IgE inhibition assay
Individual patient sera or serum pools of equals volume of 10 sera from birch pollen allergic patients was used for specific serum IgE 4 inhibition assays. All patients had a clinical history of birch pollinosis and were RAST class 2 or more against birch extract. Information with respect to clinical history of apple allergy was not available. rBet v 1 was biotinylated at a molar ratio of 1:5 (rBet v 1:biotin). The inhibition assay was performed on ADVIA Centaur System (Bayer, Kgs. Lyngby, Denmark) as follows: A serum sample (25 µl) was incubated with paramagnetic beads (solid phase) coated with a monoclonal mouse anti human IgE antibody (ALK-Abelló, Hørsholm, Denmark), washed, resuspended and incubated with a mixture of biotinylated rBet v 1 and inhibitor (nonbiotinylated molecules i.e. rBet v 1, rMal d 1 or derivate molecules) in dilution series. The amount of biotinylated rBet v 1 bound to the serum IgE on the solid phase was estimated from the measured relative light units (RLU) after incubation with acridinium-ester labeled streptavidin. The degree of binding was calculated as the ratio between the RLU's obtained using buffer and rBetv 1, rMal d 1 or derivates as inhibitor, respectively.
Histamine release in human basophils
Heparinized blood (20 ml) was drawn from birch pollen allergic patients with a history of seasonal hay fever, stored at room temperature, and used within 4 hours. 100 µl of pipes buffer pH 7.4 or 100 µl of allergen dilutions in Pipes buffer pH 7.4, 1 ng, 3 ng, 10 ng, 30 ng, 100 ng, 1000 ng of rBet v 1 (Z80104), rMal d 1 (Q8L6K9) or mutated rMal d 1 variants were added to 96 well plates in triplicates. Plates were preheated to 37°C before 100 µl of preheated (37°C) blood, diluted 1:5 with Pipes buffer pH 7.4, were added to wells with different allergen dilutions or Pipes buffer. Plates were incubated 30 minutes at 37°C before centrifuged 10 minutes at 800g in a centrifuge with a plate-rotor. Supernatants from each of the wells were transferred to wells in new micro-titer plates that were lid and sealed with sealing tape before incubated at -20°C. All histamine release experiments were performed in triplicates. were colored red and conservative substitutions were colored blue in all shown models. Substitution of amino acid residues within the following groups were considered conservative: Val-Leu-Ile-Met, Ser-Thr-Cys, Phe-Tyr-Trp, Asp-Glu, Asn-Gln, and LysArg-His. Epitope grafting The mAb BV16 binds an epitope on Bet v 1. Previously, the precise epitope was identified from the crystal structure of the Bet v 1-BV16 Fab complex (19) and a clear inhibition of birch allergic patients' serum IgE by mAb BV16 was shown (19) illustrating the relevance of the BV16 defined epitope on Bet v 1 for IgE-binding. Here, the requirements for Bet v 1-specific antibody cross-reactivity between Bet v 1 and Mal d 1 were investigated in further detail in a model system including anti-Bet v 1 mAb BV16 together with rBet v 1, rMal d 1 and variants of Mal d 1 ( Table I) . The x-ray structure of the complex revealed 16 amino acid residues (Figure 2A figure 3D displays the modeled molecular surface of Mut-2760 that contains mutations intended to reduce surface similarity to Bet v 1. Here, three residues N28, K32, E45 shared between Mal d 1 and Bet v 1 were substituted with residues differing from the ones found in the corresponding positions of known Bet v 1 isoforms. These residues were chosen for substitution based on previous data showing that they are critical residues in Bet v 1 for binding birch allergic patients serum IgE antibodies (20) .
RESULTS

Serum IgE antibody cross-reactivity
separated from the epitope defined by mAb BV16. As seen from figure 3C Mut-2762 contains a surface area shared with Bet v 1 that is very similar to "Patch 4", shown in figure 1B, that is shared between a subgroup of naturally occurring isoforms of Mal d 1 and Bet v 1. In Mut-2781, Mut-2782 and Mut-2762 mutations are located in surface areas that on naturally occurring Mal d 1 isoforms are specific to Mal d 1, and all targeted residues were substituted to residues that are present in the corresponding positions in Bet v 1. In contrast,
Maintained structural integrity of rBet v 1, rMal d 1 and mutated rMal d 1 variants
In order to confirm the structural integrity of wild type and mutated molecules the presence of secondary structure elements were analyzed by circular dichroism (CD) spectroscopy. respectively. This suggests that the containment of secondary structure elements is unaffected by the introduced point mutations and that all of the molecules have maintained structural integrity. CD spectroscopy was not applied to Mut-2782.
However, BV16 binds a conformational epitope on Mut-2781 and Mut-2782 with identical kinetics strongly indicating identical folding patterns. Therefore, in this study the reported effects of introducing mutations was in all cases caused by local changes in surface topography and charge distribution and was not caused by loss of overall structure integrity. Blood obtained from the same five individual patients were used in basophil histamine release assays, figure 5 (right column). Here, rBet v 1 triggered strong histamine release responses with basophils from all patients whereas notable patient-to-patient variations were seen with rMal d 1. In basophils from patient (n) no histamine release occurred within the measured antigen concentration range. In basophils from patients (o), (p) and (q) 10 to 100-fold higher concentrations of rMal d 1 were needed to initiate histamine release when compared to rBet v 1. In basophils from patient (r) the difference was considerable less i.e. 0 to 3-fold. Still, rMal d 1 had the ability to reach histamine release levels (maximum release) equal to those obtained with rBet v 1 in basophils from four patients (o, p, q, r). The Mal d 1 variant Mut-2760 with point mutations that reduce surface similarity to Bet v 1 affected histamine release in basophils from individual patients differently. As with wildtype rMal d 1 no histamine release occurred within the measured antigen concentration range when testing basophils from patient (n). With basophils from patient (o) histamine release was abolished in the measured antigen concentration range. In basophils from patient (p) a 10-fold reduced potency of Mut-2760 to trigger histamine release was seen compared to Mal d 1. In basophils from patient (q) and (r) no difference was seen.
DISCUSSION
Bet v 1 in complex with an antibody fabfragment from the mAb BV16 raised against natural Bet v 1 has previously been crystallized (19) . In the present study the molecular surface of Mal d 1 which shares 60% amino acid identity to Bet v 1 and is not recognized by mAb BV16 was altered by introduction of five point mutations. After these alterations all of the 16 amino acid residues that constitute the BV16 epitope on the surface of rBet v 1 were present in the corresponding surface area on the figure 4A ) and serum pool B, with IgE reactivity to only birch (figure 4B) only showed modest differences in IgE binding capacities to rMal d 1 implying that even small differences among birch allergic patients' IgE repertoires may determine the ability to potentiate allergic reactions to apple and may determine whether or not a particular patient experience OAS.
Here, we show that changing the allergen epitope composition by increasing or reducing the surface similarity to Bet v 1 in confined surface areas on Mal d 1 variants has a huge impact on the histamine release patterns obtained with basophils from birch allergic individuals. Amino acid residues E45, P108, N28 and K32 all present in surface structures on Bet v 1 that are conserved among the group 1 Fagales allergens have previously been demonstrated to be critical residues for binding of birch allergic patients serum IgE to Bet v 1 (23) . In later studies with the homologous protein from cherry, Pru av 1, residues E45 (24) and N28 (25) have likewise been identified as critical residues for IgE binding. Here we show (figure 5) notable differences between birch allergic patients' basophil histamine release profiles upon testing of wild type rMal d 1 and the mutated variant Mut-2760 (N28T, K32Q, E45S) with point mutations that decrease surface similarity to Bet v 1. This result illustrates that allergic patients' IgE repertoires can be expected to vary from patient to patient and that different IgE antibodies binding different epitopes on Mal d 1 may be responsible for OAS in individual patients. In addition, the unresponsiveness toward Mut-2760 seen with blood from patient o suggests that histamine release in this patient caused by wild type rMal d 1 is due to the presence of few or as little as two different IgEbinding epitopes. This result may explain why some birch allergic patients suffer from OAS to apple despite the result in figure 4 showing effectively no inhibition of serum IgE-binding to Bet v 1 by Mal d 1.
In addition, the classical view states that the minimum requirements for basophil-and mast cell activation involves cross-linking of antigen by two receptor-bound IgE antibodies that binds two non-overlapping epitopes on the same antigen. However, it has been hypothesized (26) that one high affinity IgE antibody on the surface of an effector cell may act as a stable surface anchor hereby facilitating binding to a second IgE antibody even if the second antibody involved binds the antigen with very pour affinity. This theory was recently supported by data from basophil activation experiments with a panel of humanized recombinant IgE antibodies binding the house dust mite allergen rDer p 2 with low, medium or high affinity (15) . Here, the combination of a single high affinity IgE specificity combined with a single low affinity IgE specificity was almost as effective as the combination of two high affinity IgE specificities and both combinations resulted in potent histamine release responses. Therefore, whether or not an individual suffers from OAS may be determined by the existence of a single IgE antibody specificity binding a single "birchlike epitope" present on Mal d 1 with medium to high affinity causing effector cell activation through cross-linking of antigen in complexes with low affinity IgE antibodies. Together, this indicates that the number of "birch-like epitopes" in Mal d 1 bound by high affinity IgE that is responsible for antibody crossreactivity in a particular birch allergic patient may be few and interestingly that low-affinity IgE antibodies may play an important role in cross-allergies. Specific immunotherapy (SIT) is a highly effective treatment of allergic disease that reduces both the immediate allergic symptoms as well as late phase responses (27) . Current treatment depends on the use of standardized allergen extracts administrated to patients for a period of 3-5 years. SIT based on subcutaneous injection of allergen extract is associated with a small but significant risk of inducing systemic allergic adverse reactions. Several concepts for the improvement of vaccines for subcutaneous SIT have therefore been proposed. Most concepts aim for a reduction in the anaphylactic potential of the vaccine component either through disruption of the tertiary structure of the allergen e.g. allergen derived peptides (28;29) or through disruption of epitopes by substitution of surface exposed single amino acid residues on structurally intact allergens (20;23) . A vaccine for SIT based on allergen derived peptides focuses solely on a modulation of the existing T-cell response whereas the latter concept also focuses on maintaining surface structures for the induction of so called blocking IgG antibodies (30) (31) reactive with the native allergen. The approach, however, is hampered by the heterogeneity of allergic patients' responses and the concept may be dependent on the introduction of mutations in numbers leading to structural destabilization of the resulting molecule.
Conceptually, a novel approach to rational allergy vaccine engineering might be based on epitope grafting i.e. the building of allergen specific antibody binding epitopes into a stable homologous scaffold molecule that with respect to binding allergic patients' IgE antibodies ideally should be inert. The idea is to generate a vaccine with reduced anaphylactic potential by splitting the allergen surface onto separate vaccine molecule components. Ideally, the size of the surface graft on each scaffold molecule should allow for several overlapping epitopes to exist but restricted in size to allow only one IgE antibody to bind within the surface graft at the same time. Potentially, such a multi component based vaccine will be unable to activate effector cells as this would require specific IgE antibodies to bind two or more non-overlapping epitopes on the same scaffold molecule. The vaccine, however, would be able to generate blocking IgG antibodies directed against all the overlapping epitopes present within the grafted surface areas present on the different vaccine components. In line with the results of other studies (32;33) we have demonstrated reactivity with Mal d 1 of Bet v 1-specific T-cell lines and in addition, the T-cell recognition of rMal d 1 variants was not influenced by the mutations investigated in the present study (see Fig E2 in the supplemental data section). Still, a scaffold molecule that is very distantly related but structurally similar to the allergen in question would probably lack most if not all allergen specific T-cell epitopes. Grafting of both specific B-cell epitopes as well as specific Tcell epitopes might therefore be necessary in order to obtain a suited vaccine candidate. The grafting of the BV16 epitope from Bet v 1 to Mal d 1 performed in this study was a first attempt to follow such a strategy and this study shows that it is possible to shape a conformational B-cell epitope onto the surface of a homologous scaffold molecule having 60% amino acid identity to Bet v 1 and maintain epitope functionality. Further work is needed to show whether a conformational epitope can be grafted onto a homologous scaffold molecule that is exceedingly more distant related to Bet v 1. Tables and figures   Table I 
